GOTHENBURG, Sweden and FREIBURG, Germany, May 12 /PRNewswire/ -- AngioGenetics AB and the Tumor Biology Center Freiburg (TBCF) today announced a research agreement with the aim to jointly validate known drugs with an angiogenesis modulating effect for the treatment of cancer, ischemic heart disease, and eye diseases. The angiogenesis-modulating drugs have been identified in a screen performed at TBCF using the Spherogenex(TM) screening platform. AngioGenetics AB has acquired the rights to the results of this screen and further validation of the compounds will be performed jointly, with the aim to obtain strong use patents.
"The screen performed by the skilled scientists at TBCF holds great promise and we are confident these discoveries have the potential to improve current angiogenesis based therapies" said Mattias Kalen, CEO of AngioGenetics AB."
"It's a long road from the identification of a potential drug, through pre-clinical validation, to successful clinical trials," said Prof. Hellmut Augustin, Head of the Department of Vascular Biology and Angiogenesis Research at the TBCF. "We are very pleased to have teamed up with AngioGenetics, thereby enhancing further development of the discoveries."
The Tumor Biology Center Freiburg is a privately-owned University of Freiburg-affiliated Oncology Hospital and Research Institution located in Freiburg, Germany. With a longstanding record in the field of protein kinase research and kinase inhibitor development, TBCF has an active bench-to-bedside concept covering the spectrum from preclinical target identification and validation, in vitro and in vivo compound screening programs to clinical trials of novel anti-cancer drugs. The Spherogenex(TM) Unit of TBCF has its main focus in the identification and validation of novel angiogenesis-modulating compounds running an integrated in vitro and in vivo compound validation platform for in house development and for external service-based screens for the pharmaceutical industry. For additional information about TBCF, please visit http://www.tumorbio.uni-freiburg.de/.
About AngioGenetics AB
AngioGenetics AB is a biotechnology company located in Gothenburg, Sweden, focusing on discovery, development, and commercialization of novel angiogenesis-modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. AngioGenetics AB has developed solid platforms for drug and target discovery, and these provide a pipeline of novel lead compounds and use-patent protected drugs to fulfill industry demands for such products.
For additional information about the company, please visit http://www.angiogenetics.se/.
CONTACT: Contacts: Tumor Biology Center, Prof. Hellmut Augustin,+49-761-206-1500, AngioGenetics AB, Mattias KalÃ?Â©n, CEO,+46-31-773-3553